PROfound Study – PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations – Maha Hussain

Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it’s intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate…

Read the full article here

Source: UroToday

Categories: Rare Disease

Tags: PROfound

Tweets with this article

UroToday.com

#PROfound study - PARP-inhibitor Olaparib in advanced #ProstateCancer patients with specific tumor mutations discussion by Maha Hussain, MD, FACP, FASCO @LurieCancer and @CaPsurvivorship @NUFeinbergMed on UroToday > https://t.co/jhg03Acut8 @AstraZeneca @Merck @FoundationATCG https://t.co/5Trk1lZysb

Sign up

UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…

UroToday.com April 23, 2025

Improving Prostate Biopsy Tissue Quality for Better Pathological Analysis – Kenneth Iczkowski

Zachary Klaassen interviews Kenneth Iczkowski about optimizing prostate biopsy techniques from a pathologist’s perspective. Dr. Iczkowski discusses significant limitations of standard notch-based needle biopsies, highlighting…

UroToday.com April 22, 2025

Initial Linguistic and Cultural Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI) in Spanish – Beyond the Abstract

erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.

UroToday.com April 21, 2025

Landscape of Approved and Upcoming PSMA Imaging Agents “Presentation” – Amir Iravani

At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…

UroToday.com April 21, 2025

Unveiling the Molecular Hallmarks of Peyronie’s Disease: A Comprehensive Narrative Review – Beyond the Abstract

Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone,…

UroToday.com April 19, 2025

Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II Seminoma: A Systematic Review and Meta-Analysis of Safety and Oncological Effectiveness – Beyond the Abstract

Testicular cancer, Testicular germ cell tumor (TGCT), Retroperitoneal Lymph Node Dissection (RPLND), pathological lymph node staging, clinical stage (CS) II seminomatous TGCT.

UroToday.com April 19, 2025

Advancing Holmium Laser Enucleation of the Prostate Outcomes Reporting: An Assessment of Patient-Reported Outcomes in the Literature – Beyond the Abstract

Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), Holmium Laser Enucleation of the prostate cancer (HoLEP), Advancing Holmium Laser Enucleation, American Urological Association Symptom…

UroToday.com April 18, 2025

Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis – Ken Herrmann

Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…

UroToday.com April 17, 2025

Outcomes and Efficacy of Magnetic Resonance Imaging-Compatible Sacral Nerve Stimulator for Management of Fecal Incontinence: A Multi-Institutional Study – Beyond the Abstract

Fecal Incontinence, Sacral neuromodulation, sacral nerve stimulation (SNS), Sacral Nerve Stimulator for Management of Fecal Incontinence, overactive bladder, InterStim™ device.

UroToday.com April 16, 2025

Sign up

UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…

UroToday.com April 16, 2025

Related Articles